Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 97Myeloid 82Sarcoma 17Gastrointestinal 17Lymphoid 14Tumor-Agnostic 8Dermatologic 5Gynecologic 2CNS 2Head & Neck 1Breast 1

Conditions

Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Glioma 1

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × nilotinib × CNS × Clear all
NCT01140568 2020-05-05

Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

University of California, San Diego

Phase 2 Completed
38 enrolled 8 charts
CNS

Glioma

NCT01275586 2017-04-12

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Indiana University

Phase EARLY_PHASE1 Completed
6 enrolled 7 charts
CNS

Neurofibroma, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡